Sign In
Buy MRK
$113.87
-1.62 (-1.40%)
At Close: Jun 18, 2026
RAHWAY, N.J.--(BUSINESS WIRE)--Update on KEYFORM-007 Trial Evaluating Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1+ MSS mCRC.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA Receives New Approvals in Japan for Certain Patients With NSCLC and Radically Unresectable Urothelial Carcinoma.
MRK Gets Positive CHMP Nod for Keytruda in Two Gynecologic Cancers
10:56am, Monday, 23'rd Sep 2024
The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types of gynecologic cancers.
Merck Loses Around $32B in 3 Months: Time to Sell the Stock?
10:56am, Friday, 20'th Sep 2024
Declining estimates and the recent price drop make investors skeptical about holding MRK stock.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Gynecologic Cancers.
Merck (MRK) Stock Dips While Market Gains: Key Facts
06:56pm, Thursday, 19'th Sep 2024
In the closing of the recent trading day, Merck (MRK) stood at $117.23, denoting a -1.19% change from the preceding trading day.
Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial
02:33pm, Thursday, 19'th Sep 2024
Summit Therapeutics' ivonescimab shows improved efficacy over Merck's Keytruda in Phase III trials, targeting both PD-1 and VEGF, potentially expanding the PD-1 inhibitor market. Despite risks, Summit
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
11:25am, Thursday, 19'th Sep 2024
The FDA approves MRK's Keytruda for first-line treatment of malignant pleural mesothelioma. This marks Keytruda's first approval for the given indication.
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
10:05am, Thursday, 19'th Sep 2024
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
3 Fantastic Dividend Stocks To Avoid The 'Lost Decade'
07:30am, Thursday, 19'th Sep 2024
JPMorgan forecasts a significant drop in S&P 500 returns, suggesting a shift from the high gains of the past decade to lower future performance. Valuations are currently unfavorable, and with rising r
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
04:01pm, Wednesday, 18'th Sep 2024
MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.
Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?
10:31am, Wednesday, 18'th Sep 2024
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy
Merck & Co., Inc. (MRK) Bank of America Global Healthcare Conference (Transcript)
10:22am, Wednesday, 18'th Sep 2024
Merck & Co., Inc. (NYSE:MRK ) Bank of America Global Healthcare Conference September 18, 2024 6:40 AM ET Company Participants Joseph Romanelli - President, Human Health International Peter Dannenbaum
Merck wins first FDA approval for Keytruda as a treatment for mesothelioma
07:39am, Wednesday, 18'th Sep 2024
Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated with
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA,
